Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TUB-040 in Platinum-resistant Ovarian Cancer and NSCLC
NCT06303505Phase 2Recruiting
- Sponsor
- Gilead Sciences
- Start
- Jun 2024
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of TUB-040 in ovarian cancer and non-small cell lung cancer (NSCLC) (5 arms), sponsored by Gilead Sciences. Primary endpoints: Dose-limiting Toxicities at 21 days, Treatment-Emergent Adverse Events up to 3 years and 1 more. Started Jun 2024; status: recruiting.
02
Drugs
TUB-040
03
Conditions
ovarian cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06303505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06303505.